There is a newly created Tasigna multi-district litigation (MDL) for those Tasigna drug injury lawsuits filed in the federal court system. We get some of the reasoning for this consolidation of Tasigna side effects cases from the August 10, 2021, JPML Transfer Order issued for IN RE: TASIGNA (NILOTINIB) PRODUCTS LIABILITY LITIGATION, MDL No. … [Read more...]
Drug Injury Lawsuits: List of Some Cases Filed in First Half of 2021
A drug injury lawsuit is a personal injury case or a wrongful death case involving a serious drug side effect or a severe adverse drug reaction. Here are some of the prescription medications for which drug injury lawsuits were filed against the responsible pharmaceutical company in the first half of 2021: Xeljanz Beovu Elmiron … [Read more...]
Tasigna Lawsuits Update: New Jersey MCL and Federal Court MDL Consolidations
We are currently investigating Tasigna side effects cases as possible Tasigna drug injury lawsuits against Novartis for patients who have developed some serious medical conditions during their use of Tasigna. In early June 2021, the New Jersey Supreme Court consolidated Tasigna drug injury lawsuits filed against Novartis Pharmaceuticals Corp. … [Read more...]
Do Leukemia Drug Tasigna Side Effects Need Stronger Warnings In US?
In April 2013 a so-called “Dear Doctor” letter was sent out in Canada by Novartis Pharmaceuticals Canada Inc. warning about some serious side effects associated with Tasigna and a drug label change with new information concerning those Tasigna side effects. Significantly, there was no similar “Dear Doctor” letter sent in the US by Novartis … [Read more...]
Risk of Hepatitis B Reactivation Associated With Gleevec And Iclusig
Currently available medicines in the BCR-ABL TKIs class of drugs include Gleevec and Iclusig, as well as Tasigna, Bosulif, and Sprycel. These BCR-ABL tyrosine kinase inhibitors (TKIs) are used for the treatment of specific types of blood cancers, including Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) and Ph+ acute … [Read more...]